3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, were originally designed to reduce cholesterol biosynthesis and have been extensively used as prevention drugs against hyperlipidemia and cardiovascular conditions. Recently, these compounds have been shown to display chemopreventive activity against cancer. However, the effects of statins on cancer are not completely understood. For this reason, we have studied the cytotoxic effect of rosuvastatin and fluvastatin on three cell tumoral lines: human larynx carcinoma (HEp-2), human nasopharyngeal carcinoma (KB), and human epithelial carcinoma (HeLa). We have found that only fluvastatin has relevant activity against the tumoral cell lines assayed and the capacity to arrest G 1 -phase, whereas a significant decline was observed in the S-phase percentage. Fluvastatin IC 50 were 2.43±0.56 µ µ µ µg/mL (HEp-2), 2.29±0.19 µ µ µ µg/mL (KB), and 5.02±1.52 µ µ µ µg/mL (HeLa), whereas rosuvastatin showed poor activity. These results indicate that the cytotoxic effect of fluvastatin may not depend directly on HMG-CoA reductase inhibition. The antitumor statins effect needs further investigation.
INTRODUCTION
It has been demonstrated that abnormally high levels of serum cholesterol contribute to atherosclerosis and coronary artery disease. Statins, such as rosuvastatin and fluvastatin are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and efficiently and widely used drugs in the treatment of lipid disorders, especially hypercholesterolemia (AguilarSalinas et al., 1993; Watts and Dimmitt, 1999; Mahmoud, 2006; Anand et al., 2009) .
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properties such as antiviral (Bader et al., 2008; Bader and Korba, 2010; Jameson et al., 2010; Milazzo et al., 2010) and antitumor activities (Takahashi et al., 2006; Takahashi and Nishibori, 2007; Garwood et al., 2010) , however the antitumor molecular mechanisms by which the statin block cancer cell growth are poorly understood (Ghosh-Choudhury et al., 2010) , and there are emerging interests to explore the anticancer potentials of HMGCoA reductase inhibitors in the clinical setting, particularly in tumor sites sensitive to these agents in vitro (Chan et al., 2003) , some mechanism proposes for anticancer activities are apoptotic inducer, antiangiogenic and antimetastatic. These properties are associates with the inhibition of the synthesis of isoprenoid intermediates of the mevalonate pathway (Slawinska and KandeferSzerszen, 2008 
MATERIALS AND METHODS
Cytotoxicity assays. HEp-2, KB and HeLa cells were maintained in RMPI 1640 medium with 10% fetal bovine serum and cultured at 37°C in an atmosphere of 5% CO2 in air (100% humidity). Cells at log phase of their growth cycle were treated in triplicate at various concentrations of the test samples (0.032-20.0 g/mL), and incubated for 72 h at 37°C in a humidified atmosphere of 5% CO2. Cell concentrations were determined by the sulforhodamine B method, this colorimetric method expresses the results in grown cell percentage in relation with the control using the following formula, % grown cell = (At-Ab)/(Ac-Ab) x100, where, At= absorbance value of test compound, Ab= absorbance value of blank, Ac=absorbance value of control (Skehan et al., 1990; Philip et al., 1990; Patel and Patel, 2010; Sivacumar and Alagesaboopathi, 2008; Phadungkit et al., 2010) .
Statistical analysis
All the assays were set up in triplicate. The results (IC50) were obtained using a nonlinear regression (equation: standard curves, four parameter logistic curve) and expressed as mean ± standard deviation (SD) by the program SigmaPlot (pharmacology, standard curve analysis).
DNA content and cell cycle analysis
DNA content and cell cycle analysis were carried out according to standard procedures (Masuo et al., 1998; Nunez, 2001) . HeLa cells in logarithm phase were incubated for 48 h with fluvastatin (IC50 × 10) in DMSO according whit the protocol describe for Nunez in 2010. Cells were fixed with cold ethanol 70% (v/v) overnight and stained for 12 h at 4°C with triton X-100 (100 L), trisodium citrate (100 mg), RNase A (100 mg), propidium iodide (500 µg/mL) and filtered through nylon mesh. This study was carryout in the Centro de Investigaciones y de Estudios Avanzados del Instituto Politécnico Nacional in 2009.
The analysis of the cell cycle was performed in a Becton Dickinson FACSCalibur flow cytometer the number of acquisition was about 20,000 events. Data analysis was performed by using the Watson's model (Watson et al., 1987) implemented in the FlowJo program version 7.2.5.
Statins
Rosuvastatin was obtained from Astra-Zeneca, and fluvastatin was obtained from Sigma-Aldrich in 2008.
RESULTS
Cytotoxicity assays. We examined the cytotoxicity effect of rosuvastatin and fluvastatin on the tumoral lines Khan et al. 323 HEp-2, KB and HeLa. The experiments clearly showed only fluvastatin induced cytotoxicity in the three cell lines in a concentration-dependent manner ( Figure 1 and Table 1 ). Calculated IC 50 values are: Fluvastatin IC 50 were 2.43±0.56 µg/mL (HEp-2), 2.29±0.19 µg/mL (KB), and 5.02±1.52 µg/mL (HeLa) ( Table 1) , whereas rosuvastatin have poor activity (IC 50 >20 µg/mL). Table 2 illustrates the changes in DNA content distribution in HeLa cell line treated with fluvastatin (Nunez, 2001) . The percentage of cells in G 1 -phase was higher in the fluvastatin-treated group than in the untreated group, 60.3% vs 51.3%, whereas the S-phase was lower in the fluvastatin-treated group than in the untreated one. This statistic analysis was supporter using the Watson model. The differences between the experimental and the control were of 0.2 for fluvastatin and 0.13 for the control.
DNA content and cell cycle analysis

DISCUSSION
We found that only fluvastatin showed important activity against the three tumoral cell lines assayed (Figure 1 ). Fluvastatin IC 50 were 2.43±0.56 µg/mL (HEp-2), 2.29±0.19 µg/mL (KB), and 5.02±1.52 µg/mL (HeLa). Cell growth was concentration-dependent in the three tumoral cell lines evaluated (Figure 1 ). Rosuvastatin did not show any significant growth inhibition activity against the tumoral cell lines assayed (Figure 1) . This difference in cytotoxicity may be caused by the chemical differences in the structure. However, Kobayashi et al. (2007) has reported rosuvastatin cytotoxic activity associated with statin increasing intracellular accumulation and related to pH, maybe for the polar character of the molecule this is agree with the poor activity found (Table 1) .
Our cytotoxicity results do not support the mechanism suggested by Buchwald and Wachtershauser et al. (1992) who related the statin antitumor activity with HMGCoA reductase. In spite of being a potent inhibitor of HMG-CoA reductase, rosuvastatin did not inhibit the growth of the cell tumoral lines assayed (Table 1) .
Other mechanisms indirectly related with statins have been suggested; i.e. inhibition of ras protein activation which is important in the regulation of cell differentiation and proliferation (Goldstein and Brown, 1990) . IL-8 induction has been also suggested as its antitumoral action is mediated by activation of natural killer cells and cytotoxic T lymphocytes (Osaki et al., 1999) .
These observations suggest that the anticancer effect of statins depends on several factors which may not be directly related with the inhibition of HMG-CoA reductase, as it has been described in previous works (Perchellet et al., 2009) . Further experimental research is needed to clarify the statin antitumor mechanism(s). The flow cytometry study of the effect of fluvastatin on the cell cycle progression in a cervical cancer cell line (HeLa) showed a moderate G 1 -phase arrest after 48 h of exposure and a significant decline in the S-phase percentage compare with the control (Table 2 and Figure  2) . These results are similar to those reported for lovastatin (Cooper, 2002) . On the other hand, we have observed a significant increase in the percentage of apoptotic cells, in a similar way to those results reported by Glynn et al. (2008) for lovastatin, mevastatin and sinvastatin. In combination with the literature reports (Cooper, 2002; Glynn et al., 2008) this result indicates the importance effect of the statins in the G 1 -phase.
In conclusion we have demonstrated the cytotoxic effect of fluvastatin. Our results do not support the hypothesis that the statin antitumor mechanism may be related with the inhibition of HMG-CoA reductase as described in previous works (Buchwald, 1992; Wachtershauser et al., 1992; Slawinska and KandeferSzerszen, 2008) . Fluvastatin has been shown to be able to arrest the cellular growth in the G 1 -phase as well as to significantly decrease the percentage of cells in the Sphase. Further research is required to examine statin anticancer properties and the relation with the structure chemical.
